Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment
暂无分享,去创建一个
C. Hong | S. Jeong | J. Min | Sae-Ryung Kang | Je-Jung Lee | H. Bom | Hyeoung-Joon Kim | S. Sohn | Deok-Hwan Yang | Sung-Hoon Jung | Jae-Sook Ahn | J. Moon | D. Baek | H. Cho | Ga-Young Song | Seo-Yeon Ahn | Hwa Kyung Park | H. Park | S. Jung | G. Song | S. Jung
[1] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[2] C. Reid,et al. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. , 2019, Clinical lymphoma, myeloma & leukemia.
[3] M. Dimopoulos,et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. , 2019, Blood.
[4] J. Min,et al. 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Kihyun Kim,et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy , 2017, American journal of hematology.
[6] M. Dimopoulos,et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit , 2017, Blood Cancer Journal.
[7] Bart Barlogie,et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.
[8] J. Cheong,et al. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen , 2016, BMC Cancer.
[9] T. Werner,et al. 18F-FDG uptake and clearance in patients with compromised renal function , 2016, Nuclear medicine communications.
[10] M. Osman,et al. Impact of Renal Failure on F18-FDG PET/CT Scans , 2017, Front. Oncol..
[11] M. Dimopoulos,et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma , 2015, Haematologica.
[12] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Dingli,et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma , 2014, Blood Cancer Journal.
[14] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[15] M. Kersten,et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial , 2014, Haematologica.
[16] M. Dimopoulos,et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma , 2013, Leukemia.
[17] A. Davenport,et al. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] M. Dimopoulos,et al. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. , 2012 .
[19] R. Fanin,et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.
[20] B. Barlogie,et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Barlogie,et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.
[22] Tomio Inoue,et al. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues , 2007, Annals of nuclear medicine.
[23] T. Economopoulos,et al. Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance , 2007, Leukemia & lymphoma.
[24] G. Morgan,et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Eknoyan,et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.
[26] E. Montserrat,et al. Patients with multiple myeloma requiring long‐term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases , 1995, British journal of haematology.
[27] M. Dimopoulos,et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R. Fanin,et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.
[29] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.